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2Abstract:27
Aim: Glycogen Storage Disease Type II (GSD II or Pompe disease; OMIM; 232300) is a28
rare autosomal recessive lysosomal storage disorder resulting from deficiency of alpha29
glucosidase and accumulation of glycogen in muscle. Clinical symptoms include weakness30
of skeletal and respiratory muscles and in infants, cardiomyopathy. Patients with GSD II31
receive infusions of recombinant alpha glucosidase (enzyme replacement therapy; ERT),32
which slow progression of disease. ERT is given to males and females of all ages but as yet33
little is documented around the effects of continuing ERT during pregnancy. The objective34
of this case series was to ascertain the pregnancy outcomes of women with GSD II on ERT35
and to describe and adverse events associated with pregnancy, delivery and therapy.36
Methods: The medical records of 8 women attending the Royal Free Hospital Lysosomal37
Storage Disorders Unit were reviewed. Four of the eight women exper ienced 738
pregnancies over a per iod of 8 years.39
Results: In this series GSD II was associated with interventional deliveries but normal40
neonates. Cessation of ERT in early pregnancy resulted in deterioration of maternal41
symptoms and emergence of allergic reactions on restarting ERT.42
Conclusion: Individualised care plans for patients are required to ensure the best neonatal43
and maternal outcomes. Consideration should be given to the potential benefits to mother44
and fetus of continuing ERT during pregnancy.45
46
Key words: Glycogen Storage Disease Type II (GSD II), recombinant alpha glucosidase47
Enzyme Replacement Therapy (ERT), pregnancy, infusion reaction.48
49
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Introduction:51
Glycogen Storage Disease Type II is a rare, autosomal recessive disorder of glycogen52
metabolism.1  Mutations in the gene encoding the enzyme acid alpha￿glucosidase (GAA), 53
an enzyme which converts glycogen into glucose within lysosomes as part of54
glycogenolysis, result in reduced or absent GAA activity.1 Patients with GAA mutations55
are not able to complete this process resulting in excess lysosomal glycogen. The56
accumulation of glycogen within muscle overtime changes the muscle structure and57
subsequently function. These changes are seen most commonly within the cardiac and58
skeletal muscles with resultant clinical manifestations.2 Late onset GSD II is usually milder59
in presentation compared with the infantile onset form2, with infantile onset of disease often60
progressing rapidly. Most adults with late onset GSD II will experience progressive muscle61
weakness (most commonly proximal, respiratory and trunk muscles).2 In the context of late62
onset disease and relatively slow progression, patients reach reproductive age resulting in a63
different set of challenges to management of infantile Pompe disease. The balance between64
managing maternal symptoms and fetal safety may be difficult, especially due to the lack of65
availability of data with regard to managing enzyme replacement in these patients while66
pregnant.67
Enzyme replacement therapy (Alglucosidse alfa, Myzome®, Genzyme Sanofi) has been68
available in the United Kingdom since 2006. Little is documented of effects during69
pregnancy and the risk/benefit balance of continuing therapy during pregnancy is evaluated70
on an individual basis. No prescribing guidelines are available from manufactures when71
considering continuing or re￿starting enzyme replacement in pregnancy3.72
73
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4Methods:74
The medical records of the eight women with Pompe disease known to the lysosomal75
storage disorders unit of the Royal Free London NHS Foundation Trust were surveyed for76
information about the use of enzyme replacement therapy during pregnancy and the77
subsequent maternal and neonatal outcomes as a non-IRB quality improvement project.78
All Pompe patients had confirmed diagnosis on basis of alpha glucosidase activity and79
genotyping. Four of the eight patients were found to have experienced seven pregnancies80
since their referral to the unit, after diagnosis and after introduction or ERT in 2006.81
Verbal consent was obtained from the patients for this case series and all encounters were82
at the Lysosomal Storage Disorders Unit (a designated centre for management of lysosomal83
storage disorders including Pompe disease) of The Royal Free NHS Foundation Trust, a84
National Health Service (NHS) hospital in the United Kingdom. A total of four patients85
became pregnant over a time period of eight years (2006￿2015), with all four patients being 86
on regular routine enzyme replacement therapy around the time of conception. Prior to87
conception all patients were reviewed and examined neurologically every 6 months by88
consultant physicians in the lysosomal storage disorders unit, dieticians and89
physiotherapists. After conception, the same standard of care continued with the addition of90
obstetric and if appropriate, anaesthetic consultant input. The case histories were reviewed91
by an obstetrician and a metabolic physician. In addition patients were contacted to provide92
further detail in regard to their obstetric histories.93
94
Results:95
Since the introduction of enzyme replacement for Pompe disease in the UK there have96
been seven pregnancies in four women with Glycogen Storage Disease Type II attending97
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5the Royal Free NHS Foundation Trust Lysosomal Storage Disorders Unit. Of the98
pregnancies, six resulted in live births, and one terminated electively. Detailed parameters99
around the 7 pregnancies are given in table 2.100
101
Preconception:102
Symptoms pr ior to diagnosis included non-specific decreased effor t tolerance, lower103
back pain, non-specific whole body pain and intermittent diar rhoea. Muscle power at104
diagnosis var ied between full power at diagnosis, mild loss of proximal muscle power105
moderate loss of proximal upper limb power and lower limb power , and more severe106
loss of proximal muscle strength.107
Baseline lung function and sleep study tests were normal for three out of the four108
patients. The remaining patient had moderately-severe decreased respiratory function109
demonstrated on spirometry and confirmed type 2 respiratory which resolved with110
home nocturnal BiPAP. All patients had normal cardiac function at diagnosis. During111
pregnancy patients received dietary advice including food safety, use of high protein112
diet, folic acid, vitamin D, and avoidance of vitamin A supplements and limitation to113
no more than two por tion of oily fish per week.114
115
Enzyme replacement therapy adjustments during the pregnancies:116
The time per iod between diagnosis and commencing ERT was between 2 and 6117
months (mean 4.1 months). The mean time from star ting ERT to pregnancy was118
(22.75 months – range 8 months 2 weeks to 3 years 2 weeks. While on ERT three of119
the patients conceived for the first time while the remaining patient conceived for the120
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6fourth time. Three of the patients went on to have second pregnancies while on ERT121
(two patients becoming pregnant for the second time and one patient becoming122
pregnant for the fifth time). Enzyme replacement therapy was stopped in the first123
tr imester in all four patients. During the first pregnancy, while off therapy, only one124
of the four patients did not experience any subjective or objective muscle strength125
decline (patient 1 in table 2). Patient 1 became pregnant twice while on ERT and her126
muscle strength remained unchanged throughout. The other three patients127
exper ienced varying degrees of muscle strength decline as outlined below. ERT was128
re-star ted in the post-par tum per iod in five out of the seven pregnancies, and at129
gestations of 16/40 and 29/40 in the remaining two pregnancies. Factors influencing130
the decisions to restar t ERT were mostly dictated by the progression of symptoms off131
ERT and patient choice.132
133
Individual Courses during pregnancy:134
Patient 1 had three pregnancies and deliver ies pr ior to diagnosis and the star t of135
this review. All deliver ies were unassisted at 42/40, term and 39/40 respectively. There136
were no postpar tum or foetal complications. All three deliver ies were at secondary137
care maternity units. Dur ing both subsequent pregnancies after diagnosis of Pompe138
disease, patient 1 stopped enzyme replacement dur ing the fir st tr imester and re-139
star ted postpar tum (at 6 weeks postpar tum and 5 weeks 4 days postpar tum140
respectively). Muscle strength and lung function remained stable during both141
pregnancies. She had a normal vaginal delivery (NVD) at 41 weeks in the first142
pregnancy and C-section for breech postdates at 42 weeks in the second.143
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7Patient 2, who stopped ERT in the 8th week of pregnancy, developed objective144
proximal and distal muscle weakness while pregnant (upper limb power 4/5 ￿ 3+/5,145
lower limb 3+/5 ￿ 3/5). After this otherwise uneventful pregnancy delivered by NVD146
at 40+2 weeks she had concerns about a second pregnancy in light of her potentially147
progressive disease and opted for an elective termination of pregnancy in the first148
tr imester . She developed subjective shor tness of breath in this pregnancy; however149
her lung function tests remained normal. She did not stop ERT dur ing this time.150
In her first pregnancy patient 3 developed isolated proximal lower limb weakness151
(MRC 4/5 ￿ 3/5) after stopping enzyme in the fir st tr imester and this improved upon152
restar ting ERT at 29 weeks. She also developed subjective shor tness of breath (with153
lung function tests remaining normal), an episode of fir st tr imester vaginal bleeding154
(6/40), and nausea. She had an elective C-section at 37+5 weeks. During her second155
pregnancy while off ERT from 5 weeks, patient 3 again developed muscle weakness,156
this time more severe than the previous pregnancy. (Decrease in proximal muscle157
power – hip adductors 3/5￿ 2/5, hip adductors 3/5 ￿ 2/5, knee 3/5 ￿ 2/5). Upper limb158
muscle str ength remained stable. She also developed objective decline in respiratory159
function (FEV1 73% predicted and FVC 68% predicted) while not of ERT. This160
pregnancy was also complicated by second tr imester vaginal bleeding (27+1/40) which161
resolved spontaneously without complication, hyperemesis gravidarum, (which162
resolved at 15/40), a r ight swollen leg, shor tness of breath at rest and associated chest163
pain at 30+2/40. She was treated empir ically with low molecular weight heparin until164
investigations confirmed the absence of a thromboemolism. She also developed an165
ir r itable uterus at 33+/40 with associated abdominal pain. This was managed166
conservatively and resolved without complication. She underwent a C-section at 36+2167
weeks and recommenced ERT at 13days post-par tum.168
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8Patient 4, who stopped ERT at 6 weeks gestation, developed progressive weakness of169
both shoulder and hip muscles (MRC 4+/5 ￿ 4/5 and MRC 2+/5 ￿ 2/5 respectively).170
She had been found to have decreased FVC (48% predicted) and FEV1 (55%171
predicted), and confirmed type 2 respiratory failure at diagnosis. Despite initial172
respiratory compromise at diagnosis, this remained stable dur ing pregnancy and sleep173
studies done at 17 and 34 weeks were both normal. She recommenced ERT at 16174
weeks and had a ventouse delivery at 42 weeks.175
176
No patient had invasive prenatal testing. All patients were offered genetic counselling.177
178
Labour and delivery:179
Delivery was by spontaneous vaginal delivery for two out of the six pregnancies, and180
operative vaginal delivery (ventouse) for one of the six pregnancies, which were181
allowed to continue. The operative vaginal delivery was done in the second stage of182
labour . This patient’s bir th plan (designed by a specialist obstetr ician in a secondary183
level maternity unit) involved allowing her to labour spontaneously (with epidural184
anaesthetic) but aimed to limit the second stage to 30 minutes to prevent maternal185
exhaustion. 45 minutes into the second stage of labour she was delivered without186
complication. All three Caesarean sections were done electively or semi-electively.187
Reasons for Caesarean section included breech presentation in patient 1, elective and188
brought forward in patient 3 in the context of confirmed fetal intrauter ine growth189
retardation (IUGR) (Grade 3 emergency Caesarean section), previous Caesarean190
section in patient 3 and. No post-par tum complications were documented, regardless191
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9of mode of delivery, and in par ticular there were no post-par tum haemorrhages192
suggesting uter ine muscle function was appropr iate after delivery in all cases.193
194
Reactions to enzyme replacement therapy:195
Two of the four patients had documented and repeated reactions to the ERT (Alglucosidse196
alfa) after restarting ERT post￿partum.  Patient 2 in (table 3) had her first reaction 2 years 197
and 9 months after the first Alglucosidse alfa infusion. Her first allergic type reaction198
occurred while receiving an infusion at home and was comprised of skin and respiratory199
manifestations (hives, pruritus, tightness in the chest and throat). The first episode resolved200
with symptomatic management (Hydrocortisone and Chlorpheniramine). This patient201
continued to have multiple reactions relating to the infusions – symptoms were varied and202
included rash, shortness of breath, tightness around chest and throat, vague abdominal pain203
and itching all requiring symptomatic intervention (Salbutamol, Hydrocortisone and204
Chlorpheniramine). During two separate reactions, this patient developed cardiovascular205
involvement as a result of the infusions (low blood pressure and both episodes requiring IV206
fluid responsive to stat boluses). One episode was accompanied by anaphylaxis ￿ 207
unrecordable blood pressure, shortness of breath and decrease in oxygen saturations. This208
episode required 2 doses of IM adrenaline and fluid resuscitation. After the anaphylactic209
episode, the enzyme replacement infusions were stopped for 8 weeks. Positive IgG210
antibodies to Alglucosidse alfa were confirmed at a titre of 3200. 8 weeks after the last211
anaphylaxis episode, a desensitisation programme was commenced as an inpatient. This212
involved initially receiving 1:100th of her previous dose and increasing doses incrementally213
on a weekly basis over a period of three months. This patient had remained off ERT214
throughout the entire pregnancy after the pregnancy was confirmed (at 8+1/40 gestation).215
The first treatment interruption was 3 years 2 weeks after initially starting treatment and216
Page 9 of 21
The Journal of Obstetrics and Gynaecology Research
The Journal of Obstetrics and Gynaecology Research
10
enzyme therapy was re￿initiated 2 months post￿partum. After desensitisation, most of the 217
infusions remained uneventful with only 2 episodes of mild pruritus, which responded to218
symptomatic management.219
Patient 3 developed a first infusion related reaction 4 years and 2 months after her first220
infusion. IgG antibodies to Alglucosidse alfa were positive (titre of 1600) 2 years prior to221
the first reaction. This patient had her first break in enzyme replacement therapy 2 years 4222
months after starting treatment (1st trimester of her first pregnancy). ERT was restarted at223
29/40 gestation in her first pregnancy and in the post￿partum period in her second 224
pregnancy. No desensitization was required after stopping therapy the first time however in225
light of the previous reactions and extended time off treatment, ERT was restarted226
incrementally postpartum without complication after the second pregnancy.227
228
Discussion:229
Patients with Glycogen Storage Disease Type II are reviewed on an individual basis prior to230
starting ERT. Inclusion criteria for starting treatment according to NHS England standard231
operating procedures include: the confirmation of definitive diagnosis (enzymatic or232
genetic), muscle weakness and or respiratory compromise, impaired quality of life as a233
result of symptoms and commitment to follow the recommended protocols for attending234
treatment session and monitoring subsequent response.2 Alglucosidse alfa has been235
developed as a recombinant human acid α￿glucosidase as enzyme replacement therapy for 236
patients with Glycogen Storage Disease Type II. It is hoped that the enzyme replacement237
will restore enzymatic activity4, deplete accumulated substrate, prevent further238
accumulation and allow for repair of damaged myocytes3. Alglucosidse alfa for use in239
pregnancy is categorised as class B according to the prescribing information and class C by240
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the FDA (Food and drug adminsteration. According to the package insert3, reproductive241
studies performed in pregnant mice and rabbits at an intravenous doses of 40mg/kg/day242
(double dose than recommended use in humans), revealed no evidence of reduced fertility243
or harm to the foetus as a result of Myzome®3. There are, however, no adequate and well￿244
controlled studies in pregnant women. Therefore with the available data, the balance245
between maternal symptom control, prevention of disease progression (as a result of246
treatment interruption) and fetal safety need to be balanced in order to ensure the best247
possible maternal and foetal outcomes.248
In our recent clinical practice ERT was stopped after discussion with the women in249
regard to the risk benefit ratio out of caution during the first trimester with the intention of250
restarting after organogenesis. However, personal preference amongst patients led to delay251
in re￿initiation in two women. Stopping treatment, as demonstrated above, resulted in three 252
of the four patients developing subjective and objective decline in muscle function during253
pregnancy. This deterioration of function, with its associated physical and psychological254
consequences, requires balanced assessment. In addition to the assessment of functional255
decline while not on ERT, patient preference need to be considered. One patient (patient 2)256
decided to delay restarting ERT to the post￿partum period out of choice. This decision was 257
influenced by the occurrence of IUGR in her sisters’ pregnancy (patient 3). No one cause258
could be confidently attributed to the IUGR although recognisable risk factors, including259
smoking, were present. Despite marked decline in muscle strength and lung function,260
patient 3 elected not to restart therapy during her second pregnancy. This preference was261
largely influenced by the presence of previous allergic reactions to ERT upon restarting.262
Anti￿drug antibodies, and in some cases clinical reactions, to Alglucosidse alfa are well￿263
recognised side effects of ERT3. The two women who developed anti￿drug antibodies and 264
infusion reactions on restarting ERT after pregnancy had a varying response to ongoing265
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Alglucosidse alfa infusions. After patient 2 developed anaphylaxis requiring adrenalin and266
emergency supportive care, she was successfully desensitized using a graded regime which267
has had a good outcome. No further anaphylactic reactions have occurred however she does268
require intermittent symptomatic treatment during some infusions. Patient 3 was269
successfully desensitised and restarted on ERT after her second pregnancy.270
After analysis of the progression of these four women through seven pregnancies,271
outcomes in women with Glycogen Storage Disease Type II and the foetus can be good.272
No definitive recommendation can be made on the use of ERT throughout pregnancy273
and the relative risks and benefits should be discussed individually with the LSD physician274
and patient. This should take into account the likelihood of deterioration in respiratory and275
muscle function off ERT, the possibility of reactions on recommencing and the view that276
the health of the baby is well served by preserving the health of the mother in pregnancy.277
There are however some issues which may benefit from particular attention.278
We suggest the following considerations for management during pregnancy:279
280
Pre￿conception:281
Upon diagnosis all patients should be reviewed for appropriateness of starting ERT.282
Baseline investigations (routine bloods, neurological assessment, lung and cardiac function283
tests and if clinically indicated, a sleep study) should all be done prior to starting enzyme284
replacement therapy2. These should be repeated prior to conception to allow for meaningful285
comparison should symptoms improve or worsen. Routine monitoring for non￿pregnant 286
patients with Glycogen Storage Disease Type II ideally should include outpatient follow up287
every six months 2 (during which symptom monitoring, nutritional assessment and repeat288
blood tests are all routinely done). Lung function tests and bone health assessments should289
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be performed annually (or more frequently if clinically indicated). Sleep studies,290
echocardiograms and more extensive investigations should be done as clinically291
indicated. Disease stabilisation would be preferable prior to conception. In light of the292
autosomal recessive nature of inheritance, in non￿consanguineous families the risk of 293
offspring developing the disease is low, however genetic counselling should be offered to294
all patients ￿ ideally prior to conception.5 Other medications may require alteration to more295
‘pregnancy safe’ alternatives, if they are potentially teratogenic. (Particular attention296
should be paid to regular analgesia, which patients with GSD II frequently require). As in297
all pre￿natal care, exploration around potentially harmful social habits also require 298
addressing. Decisions to proceed with any pregnancy ultimately lie with the patient and299
extensive information, counselling and support should be made available to all pregnant300
women with GSD II.301
302
During pregnancy:303
In addition to routine obstetric care, the women with GSD II should be seen at least once304
every trimester by a specialist Lysosomal Storage Disorders (LSD) team. Anaesthetic input305
should be arranged early with local or regional anaesthesia discussed as being the306
techniques of choice, while bearing in mind muscular skeletal abnormalities may make this307
difficult.9 Discussions about mode of delivery and available options should be highlighted308
to the women, with patient involvement in the development of birth plans. All309
investigations (baseline and subsequent) should made available to obstetrics, neurology and310
anaesthetic colleagues prior to assessment and birth planning consultations. Input by311
obstetric, neurology, respiratory, anaesthetic and dietician specialists (in addition to312
metabolic consultant specialist input) should be determined on an individual case basis313
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depending on baseline and progressive symptoms, severity of disease and previous obstetric314
history. All patients should be reviewed by a specialist dietician.315
Consideration should be given to continuing ERT during pregnancy to avoid316
neuromuscular decline however if ERT is stopped and restarted monitoring should be317
performed during infusions for allergic reactions occurring after therapy interruption.318
Adjustments in body weight need to be considered, as the dose of the therapy will require319
titration accordingly. Despite multiple physiological changes which occur in pregnancy, the320
respiratory flow rates (FEV1 and PEFR) are mostly unchanged in normal pregnancies6.321
However while not on ERT women may be at risk of respiratory muscle functional322
decline7. Special attention to ongoing monitoring of respiratory function is essential with323
the addition of investigations such as a sleep study if clinically indicated (with attention to324
signs such as early morning headaches). For all women, whether on ERT during pregnancy325
or not, symptoms of worsening disease progression should be carefully graded and326
deterioration in function minimised with the assistance of physiotherapy and by restricting327
the duration without ERT on consideration and discussion of the relative risks and benefits.328
329
During labour:330
As pregnancy progresses and nears delivery, significant metabolic stress is present8.331
Avoiding maternal fatigue is a key consideration. Recognising that women with GSD II332
may tire more easily is a key consideration and they may benefit from early intervention8.333
For example, consideration should perhaps be given to a limited length of active second334
stage (pushing) with an elective assisted vaginal delivery planned, if delivery not imminent335
within a specified time period (as in patient 4’s case). This should be reviewed on an336
individual case basis. Caesarean should only be indicated for either routine obstetric337
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reasons or medical reasons relating to GSD II and clinical condition around the time of338
delivery. Addressing maternal pain and anxiety early and having clear objectives for the339
birth plan are considered desirable.340
341
Postpartum:342
All women should be reviewed by the LSD team in the postpartum period. Re￿343
commencement of ERT if initiated is appropriate. Full neurological assessment should be344
performed on the first clinical visit through to the post￿partum period to quantify and 345
identify any symptoms which worsened during this time. Care should be taken to ensure346
that patients are monitored for new onset adverse/allergic reactions to ERT on re￿347
commencement of the drug. Patients should receive advice from occupational and348
physiotherapists with respect to the safe use of baby slings, prams and buggies and lifting.349
350
Neonatal review should be as per routine protocol by the paediatric team, paying special351
attention to development and growth.352
353
Breast feeding354
No adverse effects to breast￿fed infants from mothers on ERT have been noted so far, 355
however no information is available around the safety of ERT while breastfeeding. If356
preferred, the mother may use previously expressed milk during the 24 hours after the last357
infusion and discard expressed milk during this time. Patients are encouraged to participate358
in prospective data collection.359
360
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Summary:361
Women with Glycogen Storage Disease Type II do appear to have identifiable issues362
related to pregnancy. Decline in muscle function while stopping ERT was the most363
noticeable and prevalent finding, suggesting consideration should be given to continuing364
ERT or its early re￿initiation.  ERT infusion reactions, possibly linked to therapy 365
interruptions, can be overcome with a combination of symptomatic control and/or graded366
de￿sensitisation. In this series, there was a high Caesarean section rate. There were no 367
congenital abnormalities and all of the neonates were born in good condition, although 2368
out of 6 babies were born with birth weights less than 10th centile for sex and gestation. It is369
recognised from this series that challenges exist around the administration of ERT to370
women with Glycogen Storage Disease Type II in pregnancy, however, with individual371
patient care plans, overall outcomes for both mother and foetus can be favourable.372
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G/P – Gravidity/Parity, ERT – Enzyme Replacement Therapy415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
Age at diagnosis (Years) 29 16 13 31
Alpha glusodase
(acabose assay)
Mutation
1.5
c.￿32￿13G>T 
c.1114C>T
0.15
c.1239C>G
c.2228A>G
0.13
c.1239C>G
c.2228A>G
2.6
c.￿32￿13G>T 
c.525delT
Muscle function at
diagnosis
Proximal muscle
weakness (MRC
4/5 UL+LL)
Proximal muscle
weakness (MRC
4/5 UL, 3+/5 LL)
Full power at
diagnosis
Proximal muscle
weakness (MRC
4+/5 UL, 2+/5 LL)
Lung function at
diagnosis
Normal Normal Normal FVC (48%
predicted),
Decreased FEV1
(55% predicted),
FEV1/FVC ratio
110%
Cardiac function at
diagnosis
Normal Normal Normal Normal
Sleep study at diagnosis Not documented Normal Normal Confirmed type
two respiratory
failure (high
arterial CO2)
G/P at diagnosis (pr ior
to ERT)
G3/P3 G0/P0 G0/PO G0/P0
Time ERT star ted after
diagnosis
3/12 2/12 5.5/12 6/12
Per iod from first
star ting ERT to
pregnancy
18/12 3 years 2 weeks 2 years 4 months 8.5/12
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Table 2: Pregnancy information433
434
435
Patient 1 Patient 2 Patient 3 Patient 4
First pregnancy since star ting ERT
G/P while on ERT after
pregnancy confirmed
G4/P3 G1/P0 G1/P0 G1/P0
Social habits dur ing
pregnancy
Nil Abstained from
smoking
Continued to smoke Nil
Gestation at which ERT
stopped (weeks +days)
3 8+1 Unknown (in 1st
trimester)
6
Gestation or Time post-
par tum ERT restar ted
6 weeks post
partum
8 weeks post
partum
29 weeks gestation 16 weeks gestation
Symptoms while
pregnant and not on
ERT
Muscle Power:
No change Decline in power.
Proximal LL
MRC 3+/5￿ 3/5,
UL 4/5 ￿ 3+/5.
Decline in power. UL
strength remained
unchanged. Proximal
LL MRC 4/5￿ 3/5.
Decline in power.
(Proximal UL
MRC 4+/5 ￿ 4/5
LL MRC 2+/5 ￿
2/5
Lung function:
Unchanged Unchanged. Subjective
breathlessness –
remained unchanged.
Unchanged.
Other:
Increase in early
morning headaches
(sleep study
normal).
Nil Calf pain, unexpected
falls.
Non￿specific 
increase in muscle
aches. 2xsleep
studies (17/40,
34/40 remained
stable).
Complications dur ing
pregnancy
Nil Nil Threatened
miscarriage at +/￿ 
6/40 – resolved
without complication.
First trimester
nausea (resolved
by 10/40)
Complications/interven-
tions dur ing labour
Nil Nil Nil Operative delivery
Gestation at delivery 41 40+2 37+5 42
Method of delivery Normal Vaginal
Delivery
Normal Vaginal
Delivery
Elective C/section Operative Vaginal
Delivery
(Ventouse)
Patient 1 Patient 2 Patient 3 Patient 4
Indication for C/Section
or operative vaginal
delivery
N/A N/A Elective (Early due to
confirmed IUGR)
Elective to prevent
maternal
exhaustion
Bir th weight 3969 grams 2660 grams 2540 grams 3657 grams
Percentile for sex and
gestation at bir th
Between 75￿ 91st
centile
Below 9th centile Below 9th centile Between 50th ￿75th
centile
Apgar score Unknown 9 and 10 9 and 10 8 and 10
Neonatal complications Nil Nil IUGR with low birth. Nil
Page 19 of 21
The Journal of Obstetrics and Gynaecology Research
The Journal of Obstetrics and Gynaecology Research
20
G/P – Gravidity/Parity, ERT – Enzyme Replacement Therapy, UL￿Upper Limb, LL￿Lower Limb436
Patient 1 Patient 2 Patient 3 Patient 4
Second Pregnancy since star ting ERT
G/P while on ERT after
pregnancy confirmed
pregnant
G5/P4 G2/P1 G2/P1
Social Habits dur ing
pregnancy
Nil Continued to
smoke
Continued to smoke
Gestation at which
ERT was stopped
(weeks)
7 Not stopped 5
Time post-par tum ERT
was restar ted
5 weeks post
partum
N/A 13 days post partum
Symptoms while
pregnant and not on
ERT
Muscle power
No change No change Decline in power. UL
remained unchanged.
Proximal LL 4/5 ￿
3/5, hip adductors
3/5￿ 1/5, hip
adductors 3/5 ￿ 2/5,
knee 3/5 ￿ 2/5.
Lung function
Unchanged Subjective
shortness of
breath
Subjective and
objective decline – at
34/40 FEV1 73%
predicted, FVC 68%
predicted.
Other:
Nil Nil Early morning
headaches (sleep
study normal)
Complications dur ing
pregnancy
Breech
presentation
Elective TOP –
patient choice.
1. Hyperemesis
episode at 15/40
2. Threatened
miscarriage at
27+1/40
3. Suspected DVT at
30+2/40 – excluded
on ultrasound
4. Irritable uterus at
33+6
Complications/interven-
tions dur ing labour
Nil N/A Nil
Gestation at delivery
(weeks + days)
42 N/A 36+2
Method of delivery C/Section N/A C/Section
Indication for C/Section Breech
presentation &post
dates
N/A Previous C/Section
Bir th weight 4026 grams N/A 2476 grams
Percentile for sex and
gestation at bir th
75￿ 91st centile N/A Between 25th￿50th
centile
Apgar score Unknown N/A 9 and 10
Neonatal complications Nil documented N/A Nil documented
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Table 3: Reactions to ERT437
ERT – Enzyme Replacement Therapy438
439
Antibody response to ERT
Patient 1 Patient 2 Patient 3 Patient 4
First episode N/A 2 years 9 months
after first infusion
4 years 2 months
after first infusion
N/A
Symptoms of reaction N/A Whole body
itching, hives type
rash, shortness of
breath, wheeze, 1
episode of
anaphylaxis
reaction requiring
adrenalin.
Whole body
itching.
N/A
Antibody confir med N/A IgG positive 3200
Titre
IgG positive 1600
Titre
N/A
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